Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and DisordersReview Article Published on 2023-04-012024-09-04 Journal: Journal of ocular pharmacology and therapeutics : the official journal of [Category] 대상포진, [키워드] bullous pemphigoid corneal fibrosis glaucoma bleb fibrosis losartan persistent epithelial defect TGF beta [DOI] 10.1089/jop.2022.0174 PMC 바로가기 [Article Type] Review Article
Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and DiseaseReview Article Published on 2022-11-012024-09-04 Journal: Journal of ocular pharmacology and therapeutics : the official journal of [Category] 대상포진, [키워드] Cornea losartan Neovascularization nerve growth factor neurotropic epitheliopathy rho-kinase inhibitors scarring fibrosis [DOI] 10.1089/jop.2022.0088 PMC 바로가기 [Article Type] Review Article
COVIDMED – An early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patientsShort communication Published on 2022-10-012022-10-30 Journal: Contemporary Clinical Trials Communications [Category] COVID-19, 임상, 치료법, [키워드] AE/SAE Analysis Angiotensin converting enzyme inhibitor (ACEi) Angiotensin II receptor Blocker (ARB) Arm baseline controls COVID-19 COVID-19 patients double-blinded Efficacy and safety Enrollment Final hospitalized COVID-19 patient hospitalized COVID-19 patients Hydroxychloroquine IMPROVE Lopinavir-ritonavir losartan Mortality MOST objective outcome pandemic parameter Patient Placebo placebo-controlled platform primary endpoint Randomized randomized clinical trial Randomized clinical trial (RCT) RCT Result SARS-CoV-2 score slow standard care the mean Treatment [DOI] 10.1016/j.conctc.2022.100968 [Article Type] Short communication
Efficacy of Losartan in Hospitalized Patients With COVID-19-Induced Lung Injury: A Randomized Clinical TrialCOVID-19 유발 폐 손상으로 입원한 환자에서 Losartan의 효능: 무작위 임상 시험Randomized Controlled Trial Published on 2022-03-012022-09-25 Journal: JAMA Network Open [Category] 임상, 진단, 치료제, [키워드] acute lung injury Administered Affect age analyzed Angiotensin-converting enzyme assigned blinded blockade clinical Clinical outcome clinical trials component conducted contributing to COVID-19 disrupt Efficacy eligible fraction homeostasis hospital hospital discharge hospitalized patient Human implication IMPROVE inhibitor losartan Lung injury median men mitigate Mortality Organ failure outcome oxygen participant Participants patients with COVID-19 Placebo placebo-controlled Primary outcome RAAS Randomized randomized clinical trial receptor reduce SARS-CoV-2 viral secondary significantly the United State Ventilation were measured with COVID-19 [DOI] 10.1001/jamanetworkopen.2022.2735 PMC 바로가기 [Article Type] Randomized Controlled Trial
Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial CellsPharmacology Published on 2022-01-282022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ACE2 angiotensin 1–7 Angiotensin II antagonist Captopril COVID-19 Effect losartan SARS-CoV-2 [DOI] 10.3389/fphar.2022.842512 PMC 바로가기 [Article Type] Pharmacology
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial CellsPharmacology Published on 2021-11-192022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ACE2 ACE2 expression ACEi ACEIs AEC Air-liquid interface airway airway epithelial cell airway epithelium Angiotensin II angiotensin II (A II) receptor antagonists angiotensin-converting eitzyme inhibitors angiotensin-converting enzyme 2 antagonist antagonists ARB binding Biosafety Level 3 BSL-3 Captopril cardiovascular system Cell cells change changed children Clinical data convert Culture culture media cultures disease Effect epithelium Ex vivo expression generate IFN IFNB1 IFNL2 IL-1B IL-6 Infection infection with SARS-CoV-2 inhibitors interferon kidney losartan medication modify modulate MOI multiplicity of infection not significantly different poor prognosis Proinflammatory cytokine protective effect Protein qPCR quantitative PCR receptor reduce Replication responses risk risk of COVID-19 RNA SARS-CoV-2 SARS-CoV-2 replication SARS—CoV—2 significantly the SARS-CoV-2 treated Treatment type I USA-WA1/2020 viral spike protein were assessed were infected with COVID-19 [DOI] 10.3389/fphar.2021.765951 PMC 바로가기 [Article Type] Pharmacology
Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells인간 PSC 유래 심근세포 및 1차 내피 세포에서 항고혈압 약물 치료 및 SARS-CoV-2 감염에 대한 감수성Article Published on 2021-10-122022-09-11 Journal: Stem Cell Reports [Category] SARS, 유전자 메커니즘, [키워드] ACE2 ACEi acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alter angiotensin angiotensin receptor blocker angiotensin-converting enzyme 2 angiotensin-converting enzyme inhibitor Antihypertensive drug antihypertensive medication ARB Cell cell type Coronavirus-2 COVID-19 drug treatment endothelial Endothelial cell endothelial cells Enzyme inhibitor heart hPSC-derived cardiomyocytes Immunity interferon involved Lisinopril losartan MAPK medications membrane-bound mitogen mitogen-activated protein kinase modulate multicenter trials Necrosis NF-κB not affect nuclear pathogenicity Pathways Protein protein coding gene protein coding genes protein kinase receptor receptor blocker RNA RNA sequencing SARS-CoV-2 SARS-COV-2 infection Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 signaling pathways significant difference significant differences stem cells susceptibility therapy TNF toxic effect toxic effects Transcriptome transcriptome change transcriptome changes Treatment Tumor tumor necrosis tumor necrosis factor [DOI] 10.1016/j.stemcr.2021.08.018 PMC 바로가기 [Article Type] Article
Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis폐 유래 세포 및 내피 세포에서 IL-10 유도 ACE2 mRNA 발현에 대한 예비 증거: SARS-Cov-2 ARDS 발병에 대한 의미Immunology Published on 2021-09-272022-09-11 Journal: Frontiers in Immunology [Category] SARS, 유전자 메커니즘, 진단, [키워드] “cytokine storm” ACE2 ACE2 expression ACE2 mRNA acute respiratory distress acute respiratory distress syndrome alarmin angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-inflammatory agent anti-inflammatory cytokine ARDS biguanide binding Calu Calu-3 Calu-3 cell line Cell cell type cell types cells clinic clinically COVID-19 pathogenesis COVID-19 pro-inflammatory cytokines cytokine Cytokine storm Cytokines Disseminated intravascular coagulation elevated Endothelial cell endothelial cells enzyme Evidence evidence of expressed Host IL-10 IL-1β IL-6 in vitro increase in Infection Inflammation intestinal intravascular coagulation investigated losartan lung mechanism metformin modulation Non-pulmonary observation olmesartan organism Other patients preliminary evidence pro-inflammatory cytokines PROTECT provided question receptor Regulation renal required respiratory distress SARS-CoV-2 sartans Spike protein spike protein of SARS-CoV-2 syndrome the spike protein Thromboembolism Treatment upregulate upregulation Vasculitis Viral worse prognosis [DOI] 10.3389/fimmu.2021.718136 PMC 바로가기 [Article Type] Immunology
Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like proteaseFDA 승인 항바이러스제, 항생제, 구충제, 항산화제 및 SARS-CoV-2 파파인 유사 프로테아제에 대한 세포 보호제의 용도 변경Article Published on 2021-09-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] SARS, 신약개발, 진단, 치료제, [키워드] 6-mercaptopurine ACE acting Analysis Antacid Antibiotics anticancer drugs antimicrobial antioxidant antioxidants Antiviral antivirals approved drug benzimidazole binding affinities binding affinity binding energy binding pattern binding patterns blocker bypassing candesartan Cell contagious coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 patient COVID-19 patients Critical demonstrated docking score doripenem drug Drug discovery Drug repurposing drugs expected Famotidine fatal disease FDA-approved drugs followed by Guidance highest inhibitor list losartan MD simulations mercaptopurine molecular molecular dynamics moroxydine NAD+ oxiglutatione Papain Papain-like protease pharmacokinetic Phenformin PLPro primer protease Protective provided quercetin quercitrin receptor repurposing Ritonavir Safe SARS CoV SARS-CoV-2 sulfaguanidine surface area systemically Toxicity treat Vaccine development valsartan was used zanamivir [DOI] 10.1080/07391102.2020.1784291 PMC 바로가기 [Article Type] Article
Complex analysis of the personalized pharmacotherapy in the management of COVID-19 patients and suggestions for applications of predictive, preventive, and personalized medicine attitudeResearch Published on 2021-07-162022-10-31 Journal: The EPMA Journal [Category] COVID-19, [키워드] all ethnic groups alpha-2b analysed Analysis antiviral agent approach Biomarker calculated ceftriaxone Characteristics Chloroquine clinical Clinical practice clinical trial Colchicine collected Comorbidities comprehensive analysis Coronavirus disease 2019 COVID-19 COVID-19 patient daclatasvir defined Dexamethasone drug Drug efficacy Drug score drug therapy Drug-to-drug interaction drugs ethnic group Ethnicity-based differences evaluate facilitate Frequency functional Future healthcare Gene score generate genetic difference genetic differences genetic test HCQ highest human immunoglobulin human immunoglobulin G Hydroxychloroquine immune regulator indicated Individual outcomes individuals interferon interferon alpha-2b Interferon beta-1a levofloxacin Lopinavir losartan management molecular mechanisms Optimal medication patients with comorbidity performed Personalized medicine personalized treatment pharmacogenetic pharmacogenetics pharmacogenomics Predictive Predictive preventive personalized medicine (PPPM/3 PM) Prednisone Remdesivir reported Result ribavirin Ritonavir significantly sofosbuvir suggested supplementary material the patient translation Treatment Trial Variation variations Zinc [DOI] 10.1007/s13167-021-00247-0 PMC 바로가기 [Article Type] Research